Prazosin Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are calling your office unable to fill their Prazosin prescriptions, you are not alone. An October 2025 recall of certain generic Prazosin lots due to nitrosamine contamination has created patchy but significant supply gaps across the country. This clinical brief covers the key facts your practice needs to navigate the shortage and protect your patients.

Background: The October 2025 Prazosin Recall

Specific lots of generic prazosin hydrochloride capsules were recalled in October 2025 due to the detection of nitrosamine impurities above FDA-acceptable levels. Nitrosamines are probable human carcinogens at elevated or prolonged exposure levels. This was a class-specific quality failure—similar to the sartan, ranitidine, and metformin recalls of prior years—that triggered lot-specific market withdrawal.

Because only certain lots were recalled (not all generic Prazosin on the market), supply disruptions have been uneven. Pharmacies sourcing from unaffected manufacturers may have ample stock, while others report backordering. Clinicians should be aware that patient difficulty filling Prazosin does not necessarily mean the drug is unavailable in their region—it may simply require sourcing from a different pharmacy or manufacturer lot.

Patient Populations Most at Risk

PTSD patients prescribed Prazosin for nightmares (off-label): Abrupt discontinuation can trigger a recurrence of trauma-related nightmares, sleep disruption, and hyperarousal. This population—many of whom are veterans—requires proactive management.

Hypertension patients: While Prazosin is a second-line antihypertensive per current guidelines, patients stabilized on it should not abruptly discontinue. Rebound hypertension is a genuine risk.

BPH patients: Men using Prazosin for urinary symptom relief may experience a rapid return of obstructive symptoms if their supply is interrupted.

Clinical Alternatives by Indication

For Hypertension and/or BPH:

Doxazosin (Cardura): The most direct pharmacologic substitute—same mechanism, wider therapeutic index, once-daily dosing. Generic doxazosin is typically well-stocked. Starting dose 1 mg/day, titrate to response (max 8 mg for hypertension, 8 mg for BPH).

Terazosin: Another option for combined hypertension/BPH; once-daily dosing, generally well-tolerated.

For BPH-only patients: Tamsulosin (Flomax) or silodosin (Rapaflo) are alpha-1A selective agents with minimal blood pressure effect and may be preferable for normotensive men with BPH.

For PTSD-Associated Nightmares (off-label):

Clonidine: 0.1 mg at bedtime, titrated to 0.6 mg. Antiadrenergic effect reduces nightmares and hyperarousal. Monitor for hypotension and rebound with abrupt discontinuation.

Guanfacine: 1 mg at bedtime, titrated to 4 mg. Longer half-life than clonidine; preferred by some for pediatric and adolescent PTSD patients.

FDA-approved PTSD medications: Sertraline and paroxetine are the only FDA-approved pharmacotherapies for PTSD (not specifically for nightmares). These can be incorporated into broader treatment, though they have a slower onset of action.

Prazosin Dosing Reference for PTSD

For providers who prescribe Prazosin for PTSD nightmares: the 2023 VA/DoD Clinical Practice Guidelines conditionally recommend Prazosin for PTSD-associated nightmares. For reference, clinical trial dosing in veterans typically uses:

Start: 1 mg at bedtime; titrate by 1-2 mg every 3-7 days

Mean final dose in men: 16 mg nightly + 5 mg morning dose in some studies

Mean final dose in women: 7 mg nightly + 2 mg morning in some studies

Screen for baseline hypotension before initiating; adjust existing antihypertensives to prevent additive effects

Practice Recommendations for Providers

Proactively contact high-risk patients (PTSD on Prazosin, uncontrolled hypertension) to discuss the shortage and develop contingency plans before they run out.

If writing a new Prazosin prescription, add "may substitute doxazosin or terazosin if Prazosin unavailable" to your notes or contact the pharmacy directly.

Advise patients not to abruptly discontinue and to call your office if they cannot fill their prescription within 5 days.

Consider recommending medfinder to patients with ongoing search difficulty—it systematically calls multiple pharmacies and texts patients which ones have the medication in stock.

For a detailed guide on supporting your patients, see: How to Help Your Patients Find Prazosin In Stock: A Provider's Guide. You can also learn more about medfinder for providers at medfinder.com/providers.